

Dr Carole Longson
Director, Centre for Health Technology Evaluation
National Institute for Health and Clinical Excellence
MidCity Place
71 High Holborn
London
WC1V 6NA

17th December 2010

Dear Dr Longson

Re: NSCLC - erlotinib (maintenance): ACD2

I write on behalf of the NCRI/RCP/RCR/ACP/JCCO with relation to this ACD2 consultation. We are grateful for the opportunity to respond and would like to make the following comments. Our thanks go to our clinical expert nominee, [REDACTED] for coordinating the response from the views of our experts.

1. Has all of the relevant evidence been taken into account?

Yes. We are not aware of any evidence that has been omitted, and all relevant data has been analysed critically.

2. Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

Yes. With the proviso that modelling for cost effectiveness is always contentious, the summaries are a reasonable interpretation of the evidence

3. Are the provisional recommendations sound and a suitable basis for guidance to the NHS?

We believe that the recommendations are sound.

4. Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of gender, race, disability, age, sexual orientation, religion or belief?

No.

5. Are there any equality -related issues that need special consideration and are not covered in the appraisal consultation document?

No.

Yours sincerely

A black rectangular redaction box covering the signature area.